Wuhan Hiteck Biological Pharma Receives NMPA Approval for Aponermin in Multiple Myeloma Treatment
Wuhan Hiteck Biological Pharma Co., Ltd (SHE: 300683), a Chinese biopharmaceutical company, has announced that...
Drug
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting
Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...
Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation
The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...
Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China
The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial
China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...
Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...
Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...